Thomas Wickham
Keine laufenden Positionen mehr
Profil
Thomas Wickham worked as a Senior Director in Preclinical Sciences at GenVec, Inc. from 1993 to 2004.
He then worked as a Senior Director in Preclinical Pharmacology at Lexigen Pharmaceuticals Corp.
from 2004 to 2008.
From 2009 to 2016, he worked as a Vice President in Research & Development at Merrimack Pharmaceuticals, Inc. He then worked as a Senior Vice President in Discovery at Rubius Therapeutics, Inc. from 2019 to 2020.
Wickham received his undergraduate degree from Carnegie Mellon University and his doctorate degree from Cornell University.
Ehemalige bekannte Positionen von Thomas Wickham
| Unternehmen | Position | Ende |
|---|---|---|
| RUBIUS THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2019 |
| MERRIMACK PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2016 |
Lexigen Pharmaceuticals Corp.
 Lexigen Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Lexigen Pharmaceuticals Corp. focuses on commercial physical and biological research. The company was founded by Stephen D. Gillies and is headquartered in Billerica, MA. | Corporate Officer/Principal | 01.11.2008 |
| GENVEC INC | Corporate Officer/Principal | 01.02.2004 |
Ausbildung von Thomas Wickham
| Carnegie Mellon University | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Lexigen Pharmaceuticals Corp.
Lexigen Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Lexigen Pharmaceuticals Corp. focuses on commercial physical and biological research. The company was founded by Stephen D. Gillies and is headquartered in Billerica, MA. | Commercial Services |
